| (Values in U.S. Thousands) | Aug, 2025 | May, 2025 | Feb, 2025 | Aug, 2024 | May, 2024 |
| Sales | 560,682 | 600,655 | 520,054 | 568,873 | 498,514 |
| Sales Growth | -6.65% | +15.50% | -8.58% | +14.11% | -0.77% |
| Net Income | -12,701 | 17,023 | -18,013 | 37,041 | 27,209 |
| Net Income Growth | -174.61% | +194.50% | -148.63% | +36.14% | -16.18% |
Gerresheimer Ag (GXI.D.DX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [DXE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [DXE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Gerresheimer AG provides medicine packaging, drug delivery devices, and solutions with a product range for pharma, health, well-being, and biotech. The firm operates in three segments: The plastics and devices segment consists of products for simple and safe drug delivery along with packaging for liquid and solid medicines, The primary packaging glass segment produces glass packaging products for the pharma and cosmetics industries also for food and beverage industry and The advanced technologies segment works on technical and digital solutions to improve the therapy outcome for patients. The company generates the majority of its revenue in Europe, with sales in Germany contributing the major proportion of any country.
Fiscal Year End Date: 11/30